Author Topic: (Abst.) Long-term disease activity and disability progression in RRMS patients on Tysabri  (Read 39 times)

0 Members and 0 Guests are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 8248
  • MS diagnosed 1980
  • Location: Pacific Northwest
Not much information about just how the patients taking Tysabri (or other MS drugs) are doing over time but this research concludes:


Quote
When taking into account early inflammation and the impact of natalizumab on disease activity during the initial treatment phase, a higher than expected proportion of patients showed disability progression.


From PubMed, June 8, 2019--"Long-term disease activity and disability progression in RRMS patients on natalizumab" by researchers in Amsterdam, including two who are well known in MS research--Barkhof, Uitdehaag:


https://www.ncbi.nlm.nih.gov/pubmed/31174043
« Last Edit: June 08, 2019, 09:34:28 am by agate »
MS Speaks--online for 13 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010.

 

Related Topics

  Subject / Started by Replies Last post
0 Replies
81 Views
Last post April 07, 2016, 02:12:24 pm
by agate
0 Replies
47 Views
Last post June 13, 2016, 08:20:12 am
by agate
0 Replies
62 Views
Last post April 16, 2017, 02:48:49 pm
by agate
0 Replies
84 Views
Last post May 16, 2017, 12:06:36 pm
by agate
0 Replies
84 Views
Last post August 11, 2017, 08:12:48 am
by agate